
AQST Stock Forecast & Price Target
AQST Analyst Ratings
Bulls say
Aquestive Therapeutics Inc. is well-positioned for growth due to its promising product pipeline, particularly in the no-needle epinephrine market, which is expected to drive significant revenue opportunities. The recent announcement that the FDA does not require an AdCom for its NDA of Anaphylm has positively influenced the company’s stock price, showcasing investor confidence in the potential approval of this innovative product. The combination of a strong portfolio, including established drugs like Suboxone and the anticipated approval of new therapies, supports a positive financial outlook for the company.
Bears say
Aquestive Therapeutics faces significant downside risks that contribute to a negative outlook on its stock, primarily stemming from the potential unsuccessful development of its product AQST-109. Additionally, there is an expectation of greater than anticipated revenue erosion from its licensed commercial products, which could severely impact overall financial performance. The company may also face the necessity of raising capital to strengthen its balance sheet, further complicating its financial stability amid these existing challenges.
This aggregate rating is based on analysts' research of Aquestive Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AQST Analyst Forecast & Price Prediction
Start investing in AQST
Order type
Buy in
Order amount
Est. shares
0 shares